Modificación de la prevalencia de genotipos del virus del papiloma humano en los condilomas acuminados tras la instauración de la vacuna profiláctica

Magdaleno‐Tapial, Jorge; Hernández-Bel, P.; Salvador, José María Ortiz; Casanova-Esquembre, A.; Lorca-Spröhnle, Javier; Labrandero-Hoyos, Carolina; Peñuelas-Leal, Rodrigo; Sánchez‐Carazo, J.L.; Pérez‐Ferriols, A.

doi:10.1016/j.ad.2022.05.020

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past decade, there has been a decline in HPV genotypes traditionally associated with GWs that were the primary targets of the first two prophylactic vaccines (2vHPV and 4vHPV), both in men and women. Although the prevalence of at least one of the four most common genotypes has remained stable, there has been a slight increase in infections involving multiple genotypes or at least one high-risk type [11]. Despite vaccination efforts, a gray area persists regarding data on changes in the paradigm of HPV types in GWs, highlighting the importance of this topic due to the high morbidity caused by HPV infection globally.…”

Section: Introductionmentioning

confidence: 99%

Genital Warts in Women Vaccinated against HPV in Childhood: A Systematic Review

Malheiro,

Magalhães,

Dias

et al. 2024

Vaccines

View full text Add to dashboard Cite

Human papillomavirus (HPV) is the most prevalent sexually transmitted infection among young women. Notably, more than ten years after the introduction of HPV vaccination programs in Europe, it is essential to review the real-world evidence of the incidence of anogenital warts (GWs) among women vaccinated during childhood. In this systematic review, three databases were searched for studies published between January 2008 and September 2023. Nine cohort studies were included. A total of 890,320 HPV-vaccinated women and 1,922,033 unvaccinated women were evaluated. All the studies but one investigated the 4vHPV vaccine. The incidence rate of GWs in vaccinated women ranged from 0.0 to 1650 per 100,000 person-years. The highest incidence rates were found in women vaccinated with one dose at the age of 17–19 years old and in fully vaccinated women only after 19 years of age. Similar incidence values were reported among unvaccinated women. The incidence of GWs was lower when the age at first dose was 9–11 years old. This systematic review reveals that the incidence of GWs among HPV-vaccinated women is related to the age of vaccination and the number of vaccine doses received. In the post-vaccination era, epidemiological surveillance of the incidence of GWs and their genotypes is crucial.

show abstract

Section: Introductionmentioning

confidence: 99%